09/01/18 -
Industry
Becton, Dickinson and Company (BD) has completed the acquisition of CR Bard, a transaction that was first announced in April 2017, for US$24 billion. The combined company, which will have...
24/01/17 -
Research
Protease-modulating matrix
A Chochrane review examining evidence on the effects of treatments designed to lower the levels of protease in venous leg ulcers (VLUs) has found that the evidence from clinical trials is ‘unclear’...
24/01/17 -
Research
VTE prophylaxis programme
The implementation of a Venous thromboembolism (VTE) prophylaxis programme that targeted adults admitted to a large hospital employing a multiple-strategy approach, achieved high rates of risk...
24/01/17 -
Research
Statins could play an important role in reducing the risk of venous thromboembolism, according to research by Dr Setor Kunutsor and colleagues form the Musculoskeletal Research Unit in the School of...
24/01/17 -
Industry
Portola Pharmaceuticals has announced that the FDA has accepted Portola’s New Drug Application (NDA) granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant,...